Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01924143 · ClinicalTrials.gov registry record · Phase 1
TD-9855 Mass Balance Study
A Phase 1 study of ADHD and Fibromyalgia, sponsored by Theravance Biopharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT01924143 is a Phase 1 study of ADHD and Fibromyalgia that has completed, run by Theravance Biopharma. The registered enrollment target is 6 participants, below the 190-participant average among 75 other ADHD trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01924143, a Phase 1 study of ADHD and Fibromyalgia, has completed, sponsored by Theravance Biopharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to evaluate the absorption, distribution, metabolism, and excretion (ADME) of a single oral dose of \[14C\]TD-9855
Conditions Studied
Interventions
- DRUG TD-9855
Study Locations (1)
Nebraska
- - Lincoln
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2013-10 |
| Est. Completion | 2013-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01924143
The ClinicalTrials.gov registry entry for NCT01924143 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 190-participant average among 75 other ADHD trials with a reported enrollment target (97% lower). The listed sponsor is Theravance Biopharma, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with ADHD appearing as the primary indexed condition, and to 1 intervention - of which TD-9855 is the first listed.
NCT01924143 reports 1 study location spanning 1 distinct geographic area - top geographies include Nebraska.
Frequently Asked Questions
What is clinical trial NCT01924143 about?
NCT01924143 is a clinical study titled "TD-9855 Mass Balance Study". The purpose of the study is to evaluate the absorption, distribution, metabolism, and excretion (ADME) of a single oral dose of \[14C\]TD-9855
What is the current status of trial NCT01924143?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2013-10. Estimated completion is 2013-12.
What conditions does trial NCT01924143 study?
This clinical trial studies the following conditions: ADHD, Fibromyalgia.
What interventions are being tested in trial NCT01924143?
The interventions under investigation include: TD-9855 (DRUG).
Who is sponsoring clinical trial NCT01924143?
This trial is sponsored by Theravance Biopharma, which has 38 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01924143 being conducted?
This trial has 1 study location across Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for ADHD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Trial to Assess How Centanafadine Interacts With Stimulants in the Body
RECRUITING · Phase 1
-
Vitamin D as a Therapeutic Adjunct in the Stimulant Treatment of ADHD
COMPLETED · Phase 1
-
Safety, Tolerability, PK & Efficacy of V81444 in Volunteers With Attention Deficit/ Hyperactivity Disorder (ADHD)
COMPLETED · Phase 1
-
The Reinforcing Mechanisms of Smoking in Adult ADHD
COMPLETED · Phase 1
-
Comparative Efficacy of Organizational Skills Training (OST) and Mindfulness-Based Intervention (MBI)
RECRUITING · NA
-
Target ADHD Executive Working Memory Replication Study
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.